Medscape

Etravirine: A Novel Nonnucleoside Reverse Transcriptase Inhibitor for Managing Human Immunodeficiency Virus Infection

Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.
ascopubs.org

Reverse transcriptase inhibitors reduce tumor growth in vivo and induce cell differentiation

Potentiation of apoptosis inducing activity of BL-193, an inhibitor of Bcl-XL protein, by genistein in pancreatic cancer cells No significant financial relationships to disclose. This is an ASCO ...
Monthly Prescribing Reference

Reverse Transcriptase Inhibitor Fast Tracked for Progressive Supranuclear Palsy

After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...
Business Wire

ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors

BOSTON--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, announced new data validating the ...
The American Journal of Managed Care

FDA Approval of DOR/ISL Expands HIV Treatment Options Beyond INSTIs: Amy Colson, MD, MPH

Newly FDA-approved DOR/ISL offers an INSTI-free, 2-drug HIV treatment option with durable suppression and favorable safety. AJMC: This regimen is the first nonintegrase inhibitor 2-drug combination ...
Medscape

Certain HIV Meds Linked to Reduced Alzheimer’s Risk

Use of nucleoside reverse transcriptase inhibitors (NRTIs), but not other medications for HIV, was associated with a significantly reduced risk for Alzheimer’s disease (AD) in an analysis of two ...
BioWorld

Rome Therapeutics divulges new L1RE1 and HERV-K reverse transcriptase inhibitors

Rome Therapeutics Inc. has synthesized 4’-halomethyl-cytidine phosphoramidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors ...
Morning Overview on MSN

FDA approves Merck’s Idvynso combo pill for HIV treatment

The U.S. Food and Drug Administration on April 21, 2026, approved Merck’s Idvynso, a once-daily combination pill for HIV treatment that pairs two drug classes in a single tablet. The approval gives ...
Clinical Advisor

Two-Drug, Single-Tablet Idvynso Receives FDA Approval for HIV-1

Idvynso is a new once-daily, two-drug oral regimen for adults with HIV-1 who are virologically suppressed and have no history of treatment failure.
Verywell Health on MSN

List of approved HIV antiretroviral drugs

Medically reviewed by Lindsay Cook, PharmD Key Takeaways Antiretroviral drugs help prevent HIV from replicating in the body.
News Medical

Reverse transcriptase activity found in aging and Alzheimer’s brains

Alzheimer's disease is the most common cause of dementia and affects more than a tenth of Americans aged 65 and older. The disease has proven difficult to develop new treatments for, and available ...